Literature DB >> 28988763

Treatment of Malignant Cutaneous Adnexal Neoplasms.

C Bernárdez1, L Requena2.   

Abstract

Malignant cutaneous adnexal neoplasms form a group of rare, typically low-grade-malignancy carcinomas with follicular, sebaceous, apocrine, or eccrine differentiation or a combination of the first 3 subtypes. Their clinical presentation is usually unremarkable, and biopsy is required to establish the differentiation subtype and the definitive diagnosis. Due to their rarity, no clear consensus has been reached on which treatment is most effective. Mohs micrographic surgery is considered to be the best option to prevent recurrence in the majority of patients. Radiotherapy and chemotherapy have been studied in very few cases and have rarely been shown to be effective.
Copyright © 2017 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cirugía; Cirugía de Mohs; Malignant cutaneous adnexal neoplasms; Mohs micrographic surgery; Neoplasias anexiales cutáneas malignas; Surgery; Tratamiento; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28988763     DOI: 10.1016/j.ad.2017.04.005

Source DB:  PubMed          Journal:  Actas Dermosifiliogr (Engl Ed)        ISSN: 2173-5778


  4 in total

Review 1.  Current Treatment Options for Cutaneous Adnexal Malignancies.

Authors:  Hiroyuki Goto
Journal:  Curr Treat Options Oncol       Date:  2022-03-26

2.  [Management of malignant adnexal neoplasms of the skin].

Authors:  Pia Nagel; Verena Müller; Jochen Utikal
Journal:  Hautarzt       Date:  2021-06-17       Impact factor: 0.751

3.  Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Authors:  Rami Mäkelä; Ville Härmä; Nibal Badra Fajardo; Greg Wells; Zoi Lygerou; Olle Sangfelt; Juha Kononen; Juha K Rantala
Journal:  Oncotarget       Date:  2021-05-25

4.  Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).

Authors:  Maki Ishii; Ikuko Hirai; Keiji Tanese; Takayuki Fusumae; Yoshio Nakamura; Keitaro Fukuda; Hiroshi Uchi; Kenji Kabashima; Atsushi Otsuka; Kenji Yokota; Naoya Yamazaki; Kenjiro Namikawa; Taku Fujimura; Tatsuya Takenouchi; Yuki Yamamoto; Mana Nishiguchi; Yasunori Sato; Masayuki Amagai; Takeru Funakoshi
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.